Navigation Links
Vessix to Present V2 Renal Denervation System™ for Hypertension at LINC 2012
Date:1/19/2012

LAGUNA HILLS, Calif., Jan. 18, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today that the first public presentation of its new percutaneous V2 Renal Denervation System™ for the treatment of medication-resistant hypertension will be made at LINC 2012 in Leipzig, Germany on Thursday, January 26, 2012. 

Renal denervation is a new percutaneous catheter-based technique for the treatment of medication resistant or uncontrolled hypertension. The new V2 Renal Denervation System is designed to be faster, easier to deploy and less invasive for the patient than the alternatives available today in the market.

The presentation, titled "Radiofrequency balloon-mediated renal denervation: The V2 Catheter by Vessix Vascular," will be made by Prof. med. Horst Sievert during a session for new emerging technologies for renal denervation chaired by Krishna Rocha-Singh, M.D.

Dr. Sievert, a globally recognized interventional cardiologist based in Frankfurt, Germany, is a key opinion leader in the field of renal denervation. 

Vessix's new device, the V2 System for the treatment of medication-resistant hypertension, is an over-the-wire, balloon catheter with electrodes and thermistors mounted on the exterior of the balloon to facilitate the delivery of RF energy to the nerves surrounding the renal artery. Vessix will begin its first-in-man clinical study next month.

Key benefits of the Vessix approach to renal denervation include:

  • Therapy is delivered via a balloon catheter that is quite familiar to interventional cardiologists and other physicians, thereby increasing the usability and safety profile of the device.
  • Ability to deliver RF treatment in as little as thirty (30) seconds per artery, which is significantly faster than the only other competitively marketed renal denervation system that takes 20-30 minutes to deliver treatment to each renal artery.
  • Rapid RF treatment time greatly increases the efficiency of the procedure, significantly reduces discomfort for the patient and provides the benefits of lower exposure to radiation, lower amount of contrast dye and, therefore, lower renal toxicity to the patient.
  •  

    About Vessix Vascular, Inc. – Vessix, initially founded in 2003 as Minnow Medical, Inc. is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries. For more information on Vessix Vascular, please visit the Company's website at www.vessixvascular.com or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at matt@allencaron.com.Contact:

    Matt Clawson or 

    Len Hall (Media)  

    Allen & Caron Inc  

    949-474-4300  

    matt@allencaron.com 

    len@allencaron.com


    '/>"/>
    SOURCE Vessix Vascular, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Vessix Vascular Completes $23 Million Financing
    2. Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
    3. Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets Eighth Annual Equity Conference
    4. Bacterin to Present at the Noble 8th Annual Equity Conference on January 17, 2012
    5. MiMedx Group, Inc. to Present at the Noble Capital Markets 8th Annual Equity Conference
    6. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
    7. Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation
    8. Ultra Clean to Present at the 14th Annual Needham Growth Conference
    9. nContacts Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
    10. WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
    11. Ambit Biosciences to Present at 30th Annual J.P. Morgan Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
    (Date:3/24/2017)... , March 23, 2017  HealthMine surveys with ... 2017 revealed that health plan members want help from ... to stay engaged in their health, 2) help closing ... integrated platform for health and 5) relevant, real-time guidance. ... and lowering healthcare costs. A ...
    (Date:3/24/2017)...  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com ... and dermatology biopharmaceutical company, today disclosed terms of ... (the "Definitive Financing") it entered into on March ... who are referred to in the Definitive Financing ... with the Securities and Exchange Commission.   ...
    Breaking Medicine Technology:
    (Date:3/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... March 27, ... ... U.S. drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 ... Assemblyman Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax ...
    (Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful for Garden ... , All through the year, Garden Media aims to provide material helpful to clients’ ... and pitching client’s key messages to gain coveted media placements, Garden Media ...
    (Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... “Fighting Infection,” which will spark a conversation on the current obstacles facing infection ... number of completely preventable deaths caused by these infections. , The print ...
    (Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... According ... Office score is invalid because it does not obey the rules Congress has directed ... full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a reduction ...
    (Date:3/24/2017)... ... March 24, 2017 , ... ... Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her ... 9--24, 2017. This sacred and spiritual journey during the Summer Solstice will ...
    Breaking Medicine News(10 mins):